---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-007220"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:33:51.409410+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kyverna appoints Naji Gehchan as Chief Medical and Development Officer; grants 425,000 option shares

## Summary
- Naji Gehchan, MD/MBA, joins as Chief Medical and Development Officer; led clinical development at Eli Lilly including imlunestrant.
- Inducement grant of options for 425,000 shares under 2024 Inducement Equity Plan; exercise price at Jan 22 closing price.
- Options vest over 4 years (25% at 1-year anniversary, remainder monthly thereafter) contingent on continued service.
- Dominic Borie, former President of R&D, transitions to Strategic Advisor to the CEO and Board.
- Gehchan brings 20+ years experience in immunology and late-stage development for Kyverna's KYV-101 CAR-T program.

## SEC filing metadata
- accession: 0000950170-25-007220
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017025007220/0000950170-25-007220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017025007220/kytx-20250121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-007220
- JSON: https://secwatch.observer/filing/0000950170-25-007220.json
- Plain text: https://secwatch.observer/filing/0000950170-25-007220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.